Daniel Junius
IDEXX LABORATORIES INC /DEAbout Daniel M. Junius
Independent director at IDEXX since March 2014; Audit Committee Chair and Finance Committee member. Former President & CEO (2009–2016) and CFO of ImmunoGen, with earlier CFO roles at New England Business Service and Nashua Corporation. Education: BA, Political Science (Boston College) and MA, Management (Kellogg School of Management, Northwestern). Age 72. Core credentials: financial acumen, executive leadership, corporate strategy, innovation/R&D oversight, and risk oversight .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| ImmunoGen, Inc. | President & CEO; President & COO & Acting CFO; EVP & CFO; SVP & CFO | 2005–2016 | Credited with transforming ImmunoGen from research-focused to one with strong clinical development and manufacturing capabilities |
| New England Business Service, Inc. | EVP & CFO; SVP & CFO | 1998–2004 | Senior finance leadership |
| Nashua Corporation | VP & CFO; various finance roles | 1984–1998 | Senior finance leadership |
External Roles
| Company | Role | Tenure | Notes |
|---|---|---|---|
| GlycoMimetics, Inc. | Director | Since Mar 2016 | Current public board |
| ImmunoGen, Inc. | Director | Nov 2008 – Jun 2018 | Former public board |
| Vitae Pharmaceuticals, Inc. | Director | Jul 2016 – Oct 2016 | Former public board |
Board Governance
| Item | Details |
|---|---|
| Committee assignments | Audit Committee (Chair); Finance Committee (Member) |
| Independence | Independent director under Nasdaq rules |
| Attendance | Each IDEXX director attended ≥75% of Board/Committee meetings in 2024 |
| Board class/term | Class II director; Class II terms expire at the 2026 Annual Meeting |
| Committee activity (2024) | Audit Committee met 9x; Finance Committee met 3x |
| Cyber/risk oversight link | Audit Committee oversees accounting, internal controls, compliance, and cybersecurity program |
| Overboarding policy | In compliance; policy caps outside boards and audit committee roles |
Fixed Compensation
| Year | Cash Fees (Director-specific) | Stock Awards (Grant Date Fair Value) | Option Awards (Grant Date Fair Value) | Total |
|---|---|---|---|---|
| 2024 | $120,000 [includes $90,000 annual retainer + $30,000 Audit Chair] | $124,940 | $124,936 | $369,876 |
Director compensation program elements (current framework):
- Annual cash retainer: $90,000; Audit Chair retainer: $30,000; no per‑meeting fees .
- Annual equity: $125,000 full‑value award (RSUs/DSUs) + $125,000 non‑qualified options (total $250,000); Non‑Executive Board Chair gets an additional $80,000 equity (not applicable to Junius) .
- Directors may defer cash/equity into DSUs under the Director Plan .
Performance Compensation
Directors do not receive performance‑metric‑based pay; equity vests on service.
| Grant/Term | Detail |
|---|---|
| Grant timing | Annual director equity grants on Annual Meeting date (May 6, 2024; next scheduled May 7, 2025) |
| Full‑value awards (RSUs/DSUs) | Target value $125,000; vest on earlier of 1 year or next Annual Meeting; DSUs credited to a hypothetical account and distributed per elections |
| Stock options | Target value $125,000; strike = market price at grant; vest on earlier of 1 year or next Annual Meeting; 10‑year term; accelerated vesting on change in control |
| Hedging/pledging | Prohibited for directors; anti‑hedging and anti‑pledging policies in place |
Other Directorships & Interlocks
| Topic | Status |
|---|---|
| Current external public boards | GlycoMimetics, Inc. (Director) |
| Committee interlocks | No Compensation Committee interlocks or insider participation in 2024 |
| Related‑party transactions | No transactions involving Junius disclosed; only item since Jan 1, 2024 related to an executive’s adult son (not a director) |
Expertise & Qualifications
- Financial acumen; executive leadership; corporate strategy; innovation/R&D oversight; risk oversight .
- Education: BA, Political Science (Boston College); MA, Management (Kellogg School of Management, Northwestern) .
Equity Ownership
Beneficial ownership as of March 8, 2025:
| Holder | Shares Owned | Options Exercisable and RSUs Vesting (≤60 days) | Total Beneficial | % Outstanding |
|---|---|---|---|---|
| Daniel M. Junius | 2,741 | 5,867 | 8,608 | * (<1%) |
Director DSUs (vested) as of March 8, 2025:
| Holder | Shares Owned | DSUs (Vested) | Total Shares + DSUs |
|---|---|---|---|
| Daniel M. Junius | 2,741 | 4,289 | 7,030 |
Ownership alignment and guidelines:
- Director stock ownership guideline: ≥6x annual cash retainer; all non‑employee directors complied as of Dec 31, 2024 .
- Anti‑hedging and anti‑pledging policies strengthen alignment with shareholders .
Governance Assessment
-
Strengths
- Deep finance and operating background (former CEO/CFO) paired with Audit Committee chair role; directly aligned with oversight of financial reporting, internal controls, and cybersecurity risk management .
- Long-standing independence with no disclosed related‑party transactions; complies with overboarding policy .
- Clear ownership alignment: meaningful equity exposure via options/DSUs; compliance with director ownership guidelines .
- Board/process quality: robust self‑assessment, independent board chair structure, and strong governance practices (majority voting, proxy access, clawback policy) .
-
Potential watch items
- Tenure and age suggest eventual refreshment under the policy requiring director retirement at the next Annual Meeting after age 75; continued succession planning is prudent (Junius is 72) .
- Director pay is market‑competitive with significant equity, but not performance‑metric‑based; investors typically accept time‑vested director equity given independence requirements .
-
Red flags
- None identified: no attendance issues disclosed (≥75% board/committee attendance across directors in 2024), no interlocks, no related‑party transactions involving Junius, and anti‑hedging/pledging policies in place .